1-Naphthalenemethanamine, N,N-dimethyl-, hydrochloride | 63722-04-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-Naphthalenemethanamine, N,N-dimethyl-, hydrochloride
• 英文别名: N,N-dimethyl-1-naphthalen-1-ylmethanamine;hydrochloride
• CAS: 63722-04-3
• 化学式: C13H16ClN
• 分子量: 221.72
• InChiKey: HICYUNOFRYFIMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.32
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  3.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• FLUORESCENCE DETECTION OF POISON OAK OIL
  申请人：The Regents of the University of California

  公开号：US20130121924A1

  公开（公告）日：2013-05-16

  The invention herein disclosed provides for compositions, methods for synthesizing said compositions, and methods for using said compositions, wherein the compositions and methods may be used to bind to and/or deactivate a poison oak oil, such as urushiol. The compositions and methods can be used to treat and/or reduce an inflammatory reaction and/or hypersensitivity to natural compounds found in poison oak, poison ivy, poison sumac, mango, lac tree, and cashew nut.

  本公开的发明提供了用于合成所述组合物的方法，以及使用所述组合物的方法，其中这些组合物和方法可用于结合和/或使毒橡树油（如漆酚）失活。这些组合物和方法可用于治疗和/或减轻对毒橡树、毒藤、毒漆树、芒果、漆树和腰果中发现的天然化合物的炎症反应和/或过敏反应。
• COMPOSITIONS COMPRISING LIPOXYGENASE INHIBITORS AND CYCLODEXTRIN
  申请人：Kipp E. James

  公开号：US20070111965A1

  公开（公告）日：2007-05-17

  The present invention is directed to formulations of inclusion complexes of lipoxygenase inhibitors and cyclodextrins having a therapeutically effective concentration of the lipoxygenase inhibitor, methods of making the same and methods of treating disease states using the same. Forming cyclodextrin complexes permits the enhancement of the aqueous solubility of lipoxygenase inhibitors which allows higher concentrations of the lipoxygenase in solution. Aqueous formulations of lipoxygenase inhibitors-cyclodextrin complexes are suitable for parenteral or oral administration for treating and/or preventing inflammatory disease states. The aqueous formulations can be lyophilized to prolong storage stability, assist in oral administration and/or provide for convenient and economical packaging.

  本发明涉及含脂氧化酶抑制剂和环糊精的包含物复合物的配方，具有治疗有效浓度的脂氧化酶抑制剂，制备方法以及使用它们治疗疾病状态的方法。形成环糊精复合物可以增强脂氧化酶抑制剂的水溶性，从而允许在溶液中获得更高浓度的脂氧化酶。脂氧化酶抑制剂-环糊精复合物的水溶性配方适用于静脉或口服给药，用于治疗和/或预防炎症性疾病状态。水溶性配方可以冻干以延长储存稳定性，帮助口服给药和/或提供方便和经济的包装。
• [EN] FAB I INHIBITORS<br/>[FR] INHIBITEURS DE FAB I
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2001027103A1

  公开（公告）日：2001-04-19

  Compounds of formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections. In said formula, (A) is (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o) or (p); (I) wherein R1 is H or C¿1-4?alkyl; R?2¿ is H, C¿1-4?alkyl or C3-6cycloalkyl; R?3¿ is (q), (r), (s), (t), (u), (v) or (w); R4 is H or C¿1-4?alkyl; (x) indicates that one of the two designated bonds is a double bond and the other is a single bond; R?5¿ is CH¿2? when the bond to which it is attached is a double bond; or R?5¿ is H or C¿1-4?alkyl when the bond to which it is attached is a single bond; R?6¿ is H or C¿1-4?alkyl; R?7¿ is H, C¿1-6?alkyl or -C0-6alkyl-Ar; Y is H, C1-4alkyl, N(R')2, NHC(O)R', NHCH2C(O)R' or NHC(O)CH=CHR'; each X independently is H, C1-4alkyl, CH2OH, OR', SR', CN, N(R')2, CH2N(R')2, NO2, CF3, CO2R', CON(R')2, COR', NR'C(O)R', F, Cl, Br, I or -S(O)rCF3; W is S or O, Q is H or C1-4alkyl; M is CH2 or O; L is CH2 or C(O); E is O or NR'; each R' independently is H, C1-6alkyl or -C0-6alkyl-Ar; and r is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.

  公开了式（I）的化合物，它们是Fab I抑制剂，可用于治疗细菌感染。在所述式中，（A）是（a），（b），（c），（d），（e），（f），（g），（h），（i），（j），（k），（l），（m），（n），（o）或（p）;（I），其中R1为H或C1-4烷基; R?2¿为H，C1-4烷基或C3-6环烷基; R?3¿为（q），（r），（s），（t），（u），（v）或（w）; R4为H或C1-4烷基;（x）表示两个指定键中的一个是双键，另一个是单键;当其所连接的键是双键时，R?5¿为CH2;当其所连接的键是单键时，R?5¿为H或C1-4烷基; R?6¿为H或C1-4烷基; R?7¿为H，C1-6烷基或-C0-6烷基-Ar; Y为H，C1-4烷基，N（R'）2，NHC（O）R'，NHCH2C（O）R'或NHC（O）CH = CHR';每个X独立地为H，C1-4烷基，CH2OH，OR'，SR'，CN，N（R'）2，CH2N（R'）2，NO2，CF3，CO2R'，CON（R'）2，COR'，NR'C（O）R'，F，Cl，Br，I或-S（O）rCF3; W为S或O，Q为H或C1-4烷基; M为CH2或O; L为CH2或C（O）; E为O或NR';每个R'独立地为H，C1-6烷基或-C0-6烷基-Ar; r为0、1或2;或其药学上可接受的盐。
• FAB I inhibitors
  申请人：Miller H. William

  公开号：US20050250810A1

  公开（公告）日：2005-11-10

  Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.

  公式（I）的化合物被揭示为Fab I抑制剂，可用于治疗细菌感染。
• COMPOSITIONS OF LIPOXYGENASE INHIBITORS
  申请人：Kipp E. James

  公开号：US20070134341A1

  公开（公告）日：2007-06-14

  Pharmaceutical compositions comprising particles of lipoxygenase inhibitor compounds having an effective average size of from about 10 nm to about 50 microns are provided. More particularly, pharmaceutical compositions of particle of a 5-lipoxygenase inhibitor compound having an effective average size of from about 50 nm to about 5 microns are provided. The pharmaceutical compositions are in the form of aqueous suspensions with the particle of the 5-lipoxygenase inhibitor compound present in concentrations of from about 5 to about 200 mg/ml. In addition, methods for making such pharmaceutical compositions are provided. In particular, microprecipitation and direct homogenization in the presence of at least one surfactant are disclosed for making the pharmaceutical compositions.

  提供了包含脂氧合酶抑制剂化合物颗粒的制药组合物，其有效平均尺寸从大约10纳米到大约50微米。更具体地，提供了有效平均尺寸从大约50纳米到大约5微米的5-脂氧合酶抑制剂化合物颗粒的制药组合物。这些制药组合物以水悬浮液的形式存在，其中5-脂氧合酶抑制剂化合物的颗粒浓度为大约5到200毫克/毫升。此外，还提供了制备这种制药组合物的方法。具体来说，揭示了使用至少一种表面活性剂进行微相沉淀和直接均质化制备制药组合物的方法。